NCT04394208 (SCOPE) is a Phase 3 clinical trial of Silymarin in COVID-19, sponsored by Cairo University.

Who is sponsoring NCT04394208?

NCT04394208 is sponsored by Cairo University.

What drugs are being tested in NCT04394208?

Interventions in NCT04394208: Silymarin, Placebo.

What condition does NCT04394208 study?

NCT04394208 studies COVID-19, Viral Pneumonia Human Coronavirus.

Is NCT04394208 still recruiting?

NCT04394208 is currently status unknown. Last updated 18 August 2020.

Last reviewed 2020-08-18 · How we verify

NCT04394208: SCOPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Silymarin in COVID-19 Pneumonia

Status unknown Phase 3 Last updated 18 August 2020

What this trial tests

Phase 3 trial testing Silymarin in COVID-19 in 50 participants. Status unknown.

Timeline

16 August 2020

Primary endpoint
30 January 2021

28 February 2021

Quick facts

Lead sponsor	Cairo University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	16 August 2020
Primary completion	30 January 2021
Estimated completion	28 February 2021
Sites	1 location across Egypt

Drugs / interventions tested

Silymarin — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →
Viral Pneumonia Human Coronavirus — all drugs for Viral Pneumonia Human Coronavirus →

Sponsor

Cairo University

Who can join

18 and older, any sex, with COVID-19 or Viral Pneumonia Human Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized placebo controlled trial to assess the clinical outcome in COVID-19 Pneumonia following administration of Silymarin owing to its role as a p38 MAPK pathway inhibitor and its antiviral, anti-inflammatory and anti-oxidant effects

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, et al · · 2022 · cited 74× · PMID 36464706 · DOI 10.1038/s41392-022-01249-8
Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review.
Hu S, Jiang S, Qi X, Bai R, et al · · 2022 · cited 68× · PMID 34762760 · DOI 10.1002/ddr.21895
Traditional Herbal Medicines, Bioactive Metabolites, and Plant Products Against COVID-19: Update on Clinical Trials and Mechanism of Actions.
Alam S, Sarker MMR, Afrin S, Richi FT, et al · · 2021 · cited 61× · PMID 34122096 · DOI 10.3389/fphar.2021.671498
Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.
Gour A, Manhas D, Bag S, Gorain B, et al · · 2021 · cited 35× · PMID 33786876 · DOI 10.1002/ptr.7092
Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.
Majnooni MB, Fakhri S, Shokoohinia Y, Kiyani N, et al · · 2020 · cited 24× · PMID 33658931 · DOI 10.3389/fphar.2020.588467
Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
Palit P, Chattopadhyay D, Thomas S, Kundu A, et al · · 2021 · cited 20× · PMID 33380375 · DOI 10.1016/j.phymed.2020.153396
<i>In silico</i> investigation and potential therapeutic approaches of natural products for COVID-19: Computer-aided drug design perspective.
Rahman MM, Islam MR, Akash S, Mim SA, et al · · 2022 · cited 18× · PMID 36072227 · DOI 10.3389/fcimb.2022.929430

Verify or expand the search:

Other trials of Silymarin

Trials testing the same drug.

NCT06922669 — Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia · NA · recruiting
NCT07123922 — Effect of Silymarin as Add on Therapy on Oxidative Stress, Pulmonary Function and Quality of Life in Stable COPD Patient · NA · enrolling by invitation
NCT07001150 — Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease · Phase 2 · recruiting
NCT06114719 — Silymarin for the Prevention of Atrial Fibrillation After Cardiac Surgery · Phase 3 · completed
NCT05595109 — Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients · Phase 2, PHASE3 · unknown

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04394208 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 18 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04394208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing